Overcoming Barriers to Discovery and Implementation of Equitable Pharmacogenomic Testing in Oncology
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results